Mycelx Di Regulatory News (MYX)

16 October 2013

Mycelx Technologies Corporation

("Mycelx" or the "Company" (AIM: MYX))

Dealing by Director

The Company announces that on 15 October 2013, Mark Clark, a Director of the Company, exercised options over 35,000 common shares of US$0.025 each ("Common Shares") under the Company's Omnibus Performance Incentive Plan 2011 (the "Plan") at a price of US$4.02 per Common Share, and exercised options over 3,333 Common Shares under the Plan at a price of US$3.87 per Common Share.

The Company further announces that it was notified by Mr Clark on 15 October 2013 that, on that day, he sold 33,333 Common Shares, representing 0.25 per cent of the present issued capital of the Company, at a price of 500p per Common Share. Following this transaction, Mr Clark continues to be interested in 5,000 Common Shares, representing 0.04 per cent of the present issued capital of the Company, and in options over 61,667 Common Shares, of which 25,000 have vested.

Exercise of Warrant

The Company announces that on 15 October 2013, John Mansfield Sr., Chairman Emeritus and co-founder of the Company, exercised a warrant over 50,000 Common Shares which have been issued and allotted in accordance with the terms of the warrant at a price of US$0.01 per Common Share.

Application has been made for the admission of 50,000 new Common Shares to trading on AIM. The shares will rank pari passu with existing Common Shares and it is expected that admission will occur at 8.00 am on 22 October 2013.

Following this transaction, John Mansfield Sr. holds 1,681,084 Common shares, representing 12.69% of the present issued capital of the Company. The aggregate number of shares shown for Mr Mansfield includes 205,082 Common shares held by Mansfield Holdings LLC, being a limited liability company controlled by Mr Mansfield.

Total Voting Rights

Following the issue of 88,333 new Common Shares referred to above, the total number of voting rights in the Company's Common Shares is 13,249,971 which may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Mycelx under the Financial Conduct Authority's Disclosure and Transparency Rules. The Company does not hold any Common Shares in treasury.

Enquiries

MyCelx Technologies Corporation +1 888 306 6843

Connie Mixon - CEO

Mark Clark - CFO

Numis Securities Limited +44 20 7260 1000

Corporate Finance/Nominated Adviser

Stuart Skinner

Jamie Loughborough

Corporate Broking

James Black

Ben Stoop

Bell Pottinger Pelham +44 20 7861 3232

Mark Antelme / Nick Lambert / Henry Lerwill